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INTRODUCTION
Several studies have explored tissue validation of T1 map-
ping [1-3]. Currently, T1 relaxation time and calculated extra-
cellular volume fraction (ECV) are accepted as reliable markers 
of the degree of diffuse interstitial fibrosis [4]. T1 mapping data 
are used in various clinical studies as early detectors of disease 
or imaging-based biomarkers guiding specific therapies. How-
ever, native T1, post-T1 and ECV values vary by equipment man-
ufacturer and according to the magnetic field strength and map-
ping sequence used [5,6] So, compared to left ventricular (LV) 
mass, volume and late gadolinium enhancement (LGE) imaging 
data, multi-vender-based multicenter T1 mapping studies have 
several limitations. Thus, standardization of T1 mapping is im-
portant. In this review, we focus on the prognostic role of T1 
mapping for various clinical disease entities.
BASIC CONCEPTS AND TECHNICAL 
ASPECTS 
The general principle of T1 mapping is to acquire multiple 
images with different T1 weights and to fit the signal intensities 
of the images to the equation for T1 relaxation. T1-weighted im-
ages are acquired at different times after inversion of the magne-
tization or at different times after a saturation pulse. Pixel inten-
sities in the finally reconstructed T1 images correspond to the 
fitted T1 values [7]. T1 mapping has an advantage in that it is a 
pixel-wise map and is objective; one disadvantage is that partial 
volume effects can lead to artifacts, but motion correction and 
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Cardiovascular disease risk stratification and prognostication are very important for treat-
ment planning. In addition, for a growing number of patients with overt symptomatic heart 
failure or asymptomatic but have structural heart disease, accurate risk stratification is es-
sential. Conventional clinical cardiovascular risk factors, several biomarkers and echo-Dop-
pler indexes are generally used to satisfy this need. However, non-invasive approaches to di-
rect structural and tissue characterization of the myocardium have not produced satisfactory 
results. The recent development of the late gadolinium enhancement (LGE) imaging allows 
fibrosis or myocardial inflammation to be visualized. A growing body of evidence for LGE-
based prognostication has been reported. However, not all patients with heart failure or at 
risk for it have been assessed with LGE. Moreover, the degree of diffuse fibrosis or inflamma-
tion cannot be easily quantified with LGE techniques. Recently, introduced T1 mapping-based 
quantification can provide the volume of extracellular space suggestive of the degree of dif-
fuse tissue fibrosis or inflammation. Even without gadolinium contrast, native T1 values can 
provide quantitative information on myocardial tissue status. Here, we review current evi-
dence for T1 mapping-based risk stratification and prognostication for various cardiac dis-
eases that can lead to heart failure or lethal arrhythmic events.
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co-registration techniques are helping to minimize these ef-
fects. T1 mapping provides an intrinsic signal from both the 
myocytes and the interstitial tissue. Native T1 is prolonged 
with fibrosis, edema and amyloid and is reduced in lipid accu-
mulation (Anderson-Fabry disease), cardiac siderosis, and 
hemorrhage in acute infarction (Fig. 1) [7]. However, when us-
ing ECV and native T1, not only fibrosis but also combined myo-
cardial inflammation should be considered [8]. Currently, most 
popular T1 pulse sequences are modified look-locker inversion 
recovery (MOLLI), shortened MOLLI (shMOLLI) and satura-
tion recovery single single-shot acquisition (SASHA) (Fig. 2) 
[7]. As previously mentioned, standardization of results across 
different instruments and sequences is important for interpre-
tation of data across various studies and centers. Currently, work 
is underway to standardize T1 mapping using a specialized phan-
tom [9]. This effort can improve the precision and accuracy of the 
T1 mapping technique and can be used in multi-center studies. 
Another approach is to standardize T1 values by calculating a Z 
score, which is a standard score. In one study, converting T1 val-
ues to Z scores significantly improved the agreement between 
SASHA and shMOLLI techniques, particularly for post-contrast 
T1 and ECV [10]. In addition, the current consensus statement 
recommends that each center derive their own normal values [11].
Usage of post-T1 requires correction by blood T1 to reduce 
time-dependent differences and effects of blood flow stasis [12]. 
ECV is calculated using gadolinium distribution mechanics after 
full saturation and steady status. Blood extracellular space should 
be considered using blood hematocrit (Hct) concentration to es-
timate intracellular volume space. As such, 1-Hct can be used as 
a proxy for the extracellular volume status of blood. Change in 1/
T1 in blood and tissue is expressed as change in longitudinal 
relaxation (ΔR1) for blood (ΔR1blood) and ΔR1 for tissue 
(ΔR1tissue), then ECV can be calculated as (1-Hct)×ΔR1tissue/
ΔR1blood [11]. To make it more convenient in practice, a syn-
thetic ECV method has recently been introduced [13]. The main 
mechanism of this method is pixel T1-based calculation of ECV 
without Hct concentration. The R1 of blood was found to have 
a linear relationship with blood Hct. The regression equations 
were: Synthetic HctMOLLI=[866.0 · (1/T1blood)]- 0.1232; 
Synthetic HctShMOLLI=[727.1 · (1/T1blood)]-0.0675 [13].
Fig. 1. A schematic representation of tissue changes in T1 measurements. (A) Lipid or iron accumulation (red dots) reduces native T1 val-
ues, irrespective of the T1 accuracy or T2 sensitivity of a given sequence. (B) Normal, minimal or no accumulation. (C and D) Accumulation 
of water (blue dots) leads to an increase in native T1, which is more pronounced in T2-sensitive sequences. (E) Similarly, scar tissue leads 
to increase in native T1. Conversely, accumulation of gadolinium contrast agents (GCAs) in extracellular space (green dots) leads to reduced 
post-contrast T1 (Adapted from Puntmann et al. Circ Res 2016;119:277-299. [4]). ECV: extracellular volume fraction.
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RISK STRATIFICATION IN THE GENERAL 
POPULATION
Normal values of native T1, post-T1 and ECV
With MOLLI sequencing, which is the most popular T1 map-
ping sequence, normal myocardial native T1 ranges from 950 
to 982 ms and thereby ECV is 25.0 to 26.9% in a 1.5 T magnetic 
field [5,6,14,15]. In a 3 T magnetic field, native T1 is somewhat 
prolonged to 1052 to 1159 ms [6,16]. Although reference values 
have been published in several studies, the current consensus 
statement recommends that each center should derive normal 
values for their specific center [11] Table 1 shows an overview 
of studies reporting normative ranges for T1-mapping indices.
Fig. 2. Representative images of T1 mapping. (A) Native T1 MOLLI map (myocardial T1 1010 ms). (B) Post-contrast T1 MOLLI map (myo-
cardial T1 615 ms). (C) ECV map (ECV=26.5%). (D) Native T1 map by MOLLI. (E) ShMOLLI and (F) SASHA (Adapted from Abdel-Gadir et 
al. Res Rep Clin Cardiol 2014;5:339. [69]). MOLLI: modified look-locker inversion recovery, ECV: extracellular volume fraction, ShMOLLI: 
shortened MOLLI, SASHA: saturation recovery single-shot acquisition, RV: right ventricular, LV: left ventricular.
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Table 1. Overview of studies reporting normative ranges for T1 mapping indices
Study
(n=participants) Pulse sequence GCAs (dose and type) T1 index
1.5 T 3.0 T
Myocardium Blood Myocardium Blood
Messroghli et al. [5]
 (n=43)
MOLLI 3(3)3(3)5 
(FA 50°)
0.15 mmol/kg gadopentetate
dimeglumine
Native T1, ms 982±46
Piechnik et al. [14]
(n=342)
MOLLI 5(1)1(1)1 
(FA 35°)
0.15 mmol/kg gadopentetate
dimeglumine
Native T1, ms 962±25 1535±76
Dabir et al. [6]
(n=102)
MOLLI 3(3)3(3)5 
(FA 50°)
0.1–0.2 mmol/kg gadobutrol Native T1, ms 950±21 1551±115 1052±23 1736±139
ECV, % 25±4 26±4
Liu et al. [15]
(n=1231)
MOLLI 3(3)3(3)5 
(FA 35°)
0.15 mmol/kg gadopentetate
dimeglumine
Native T1, ms 977±42
ECV, % 26.9±2.8
von Knobelsdorff-
Brenkenhoff
et al. [16] (n=60)
MOLLI 3(3)3(3)5 
(FA 35°)
0.2 mmol/kg gadobutrol Native T1, ms 1159±73
The number of participants per group and mean values (mean±SD) are reported for the type of sequence, T1 index, field strength and T1-
mapping indices. Post-contrast T1 measurements were typically obtained >15 minutes after contrast administration (Adapted from Puntmann 
et al. Circ Res 2016;119:277-299. [4]). ECV: extracellular volume fraction, FA: flip angle, GCA: gadolinium contrast agents, MOLLI: modified 
look-locker inversion recovery.
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Relation to sex, age and cardiovascular risk factors
There are a few general population-based studies in which 
the relationships between T1 value and conventional cardiac risk 
factors such as gender, age, diabetes, hypertension or dyslipid-
emia are reported [15,17]. The recent Multi-Ethnic Study of 
Atherosclerosis (MESA) showed post-T1 was correlated with 
age and risk factors [15]. In that study, women had a significant-
ly greater partition coefficient, ECV and native T1 than men, as 
well as lower post-contrast T1 values (all p<0.05). In general, lin-
ear regression analyses demonstrated that a greater partition co-
efficient, native T1 values and ECV were associated with older 
age in men (multivariate regression coefficients=0.01; 5.9 ms; 
and 1.04% per 10 year change; all p<0.05). ECV was also signif-
icantly associated with age in women after multivariate adjust-
ments [15]. In another MESA study, 25-minute post-gadolini-
um T1 time showed more statistically significant associations 
with cardiovascular disease risk scores (10/14 scores, 71%) com-
pared to other cardiac magnetic resonance (CMR) imaging in-
dices (e.g., native T1; 7/14 scores, 50%) and the partition coef-
ficient (7/14, 50%) in men [17]. Risk scores, particularly the 
new 2013 American Heart Association/AtheroSclerotic Car-
diovascular Disease risk score, did not correlate with any CMR 
fibrosis index [17]. Bulluck et al. [18] recently reported that 
myocardial native T1 values correlated with blood T1 and 
heart rate. However, even after adjustment for heart rate and 
blood T1, females had higher native T1 values, so gender-spe-
cific T1 values should be established at each center. Association 
with age is controversial but, in women, age correlated with na-
tive T1 values in that study. Due to short-term follow-up after 
acquisition of T1 mapping, there is currently no prognostic role 
for T1 mapping in the general population. 
Fig. 3. ECV was significantly associated with adverse outcomes in univariate Cox regression models (p<0.05 for all), whether EF was re-
duced (<45%) or preserved (EF≥45%). Despite the decreased statistical power occurring with subgroup analysis, the basis for the statisti-
cally significant interactions between ECV and EF was evident qualitatively. Associations between ECV measures at the lower end of the 
ECV spectrum and events appeared strengthened when EF was reduced (Adapted from Schelbert et al. J Am Heart Assoc 2015;4:e002613. 
[20]). ECV: extracellular volume fraction, EF: ejection fraction, CMR: cardiac magnetic resonance, HHF: hospitalization for heart failure.
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Heart failure with preserved ejection fraction (HFpEF) 
or reduced EF
An early study showed that CMR-based post-contrast T1 time 
[hazard ratio (HR), 0.99; 95% confidence interval (CI): 0.98–
0.99; p=0.046], left atrial area (HR, 1.08; 95% CI: 1.03–1.13; p< 
0.01) and pulmonary vascular resistance (HR, 1.01; 95% CI: 1.00–
1.01; p=0.03) were significantly associated with cardiac events in 
patients with heart failure (HF) with preserved ejection fraction 
(HFpEF) [19]. Patients with post-T1 times below the median 
(<388.3 ms) were at greater risk of cardiac events than the rest 
of the group (p<0.01). The extracellular matrix from LV biop-
sies as quantified using TissueFAXS technology correlated with 
T1 time. Thus, post-contrast T1 time was associated with prog-
nosis in HFpEF, suggesting post-contrast T1 as a possible bio-
marker for HFpEF [19]. In another study, Schelbert et al. [20] 
reported myocardial fibrosis with ECV measures in 1172 con-
secutive patients without amyloidosis, hypertrophic or stress 
cardiomyopathy and assessed associations with outcomes us-
ing Cox regression (Fig. 3). Adjusting for age, gender, renal func-
tion, myocardial infarction size, ejection fraction (EF), hospi-
talization status, and HF stage, higher ECV was associated with 
hospitalization for HF (HR, 1.77; 95% CI: 1.32–2.36 for every 
5% increase in ECV), death (HR, 1.87; 95% CI: 1.45–2.40) or 
both (HR, 1.85; 95% CI: 1.50–2.27). ECV improved classification 
of persons at risk and improved model discrimination for out-
comes. This suggested that myocardial fibrosis measured by 
ECV was associated with hospitalization for HF, death, or both. 
Myocardial fibrosis may represent a principal phenotype of car-
diac vulnerability that improves risk stratification. It has been 
suggested that myocardial fibrosis can be reversed, and cells 
and enzymes regulating collagen could be potential therapeutic 
targets [20]. However a more recent prospective study showed 
that MOLLI-ECV in HFpEF accurately reflected histological 
ECV and correlated with markers of disease severity; ECV≥ 
28.9% (median) was associated with shorter event-free survival 
(log-rank, p=0.028), but not after adjustment for important clin-
ical and invasive hemodynamic parameters (Table 2) [21]. The 
problems to be solved are that conventional echo-based diastolic 
functional parameters such as E/e’ were not included in the 
multivariate analysis and many patients were excluded due to 
previous pacemaker/implantable cardioverter-defibrillator (ICD) 
implantation, estimated glomerular filtration rate (eGFR)<30 
mL/min, claustrophobia, immobility and premature discontinu-
ation of CMR scanning. Even in the excluded patients, echo-de-
rived E/e’ and blood N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) measurement are possible. Thus, in clinical prac-
tice, prognostication in HFpEF patients needs further improve-
ment for patient convenience. 
Acute myocardial infarction and ischemic 
cardiomyopathy
In acute myocardial infarction patients, increased remote ECV, 
higher ECV in infarct and higher remote ECV were related to 
adverse remodeling, which suggests quantitative ECV can pro-
vide insight into the pathophysiology of LV remodeling and prog-
nosis [22]. In ST elevation myocardial infarction patients, higher 
core native T1 was related to all-cause death or first hospitaliza-
tion for HF post-discharge [23]. Although a sub-study of the 
Surgical Treatment for Ischemic Heart Failure trial failed to dem-
onstrate the utility of pre-procedural viability assessment with 
dobutamine stress echocardiography or single-photon-emission 
computed tomography to guide revascularization in patients with 
ischemic cardiomyopathy [24,25], other studies support the 
identification of myocardial fibrosis as carrying important prog-
nostic information [26]. Chen et al. [27] reported that native T1 
was an independent predictor of ventricular arrhythmia in isch-
emic cardiomyopathy. The ongoing development of new tech-
niques, particularly T1 mapping of the ECV, holds promise for 
the future as early studies suggested its complementary prog-
nostic value and its avoiding contrast administration [28]. How-
ever, whether T1 mapping-guided revascularization imaging 
can improve disease prognosis has not been studied. A summary 
of T1 mapping-based prognostication studies in ischemic heart 
disease, cardiomyopathies and valvular heart diseases are de-
Table 2. Summary of prognostic value of T1 mapping in heart failure with preserved ejection fraction 
Study Parameter End-point Univariate Multivariate Co-variates Exclusion (%)
Schelbert et al. [20] 
(n=1172)
ECV Hospitalization for heart 
failure/death
p<0.001 p<0.01 Age, eGFR, myocardial infarction 
size, gender, heart failure stage
1765/597 (34)
Mascherbauer 
et al. [19] (n=100)
Post-T1 Hospitalization for heart 
failure or death from
cardiovascular causes
p=0.01 p=0.046 Left atrial area
Pulmonary vascular resistance
NT-proBNP
Not mentioned
Duca et al. [21] 
(n=117)
ECV Hospitalization for heart 
failure/death from 
cardiovascular causes
p=0.038 p=0.978 eGFR
NT-proBNP
Right ventricular end-diastolic 
volume, pulmonary vascular 
resistance
80/197 (41)
ECV: extracellular volume fraction, eGFR: estimated glomerular filtration rate, NT-proBNP: N-terminal pro-B-type natriuretic peptide
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scribed in Table 3.
Prognostic value for various non-ischemic 
cardiomyopathies
Hypertrophic cardiomyopathy (HCM)
Many previous studies have shown that the amount of LGE 
was related to future cardiovascular events, especially sudden 
death due to ventricular arrhythmic events [29,30]. The amount 
of LGE, especially more than 15% of the LV mass, can be an in-
dication that ICD implantation might be able to prevent such an 
event [29]. However, whether a T1 map-based ECV provides 
additive prognostic value for the LGE amount is not known. Be-
cause about two thirds of hypertrophic cardiomyopathy (HCM) 
patients have LGE, the role of T1 mapping for prediction of prog-
nosis may be focused on the remaining 30% non-LGE patients 
or remote myocardium in cases with LGE. In addition, wheth-
er the average ECV or T1 value of the whole myocardium is bet-
ter than the LGE amount for prognostication is not known. Only 
one study showed that the average of whole LV post-contrast 
ventricular T1 relaxation time was signiﬁcantly reduced in pa-
tients with non-sustained ventricular tachycardia and patients 
with aborted sudden cardiac death [31]. Although the value for 
prognostication is limited, native T1 data can be helpful for dis-
criminating infiltrative cardiomyopathies, such as Fabry car-
diomyopathy or hemochromatosis from HCM in patients with 
thickened myocardium [32-35]. Compared to other disease en-
tities, the native T1 value is uniquely decreased in Fabry cardio-
myopathy [33] and hemochromatosis [35]. Native T1 data were 
shown to be independent discriminators between HCM and 
hypertension or an athlete’s heart, over and above ECV, LV wall 
thickness and indexed LV mass [36,37]. Native T1 was also use-
ful for separating positive genotype but not negative phenotype 
subjects from controls [36]. In HCM, contrast-enhanced CMR 
with T1 mapping can non-invasively evaluate regional and dif-
fuse patterns of myocardial fibrosis. These patterns of fibrosis 
occur independently of each other and exhibit distinct clinical 
associations. HCM patients with recognized genetic mutations 
have significantly more regional but less diffuse myocardial fi-
brosis compared to those without [38].
Dilated cardiomyopathy (DCM)
The role of T1 mapping is promising for non-ischemic dilat-
ed cardiomyopathy (DCM) because a typical mid-wall LGE 
pattern is not as prevalent as seen in HCM. Generally 44% (21 
to 70%) of non-ischemic DCM patients have been shown to have 
LGE [39], so theoretically, ECV might be useful in DCM patients 
without LGE. In addition, in all DCM patients, remote non-
LGE area ECV could provide significant additive information 
for risk stratification and prognostication. For instance, in one 
study, a post-T1 value >450 ms was an independent predictor of 
LV reverse remodeling at follow-up (LV systolic volume index 
Δ=24.6 mL/m2 standard error 14.6 mL/m2, p=0.0480) in pa-
tients despite the presence of LGE, even after adjusting for their 
Seattle Heart Failure Score [40]. While DCM patients with focal 
LGE demonstrated greater adverse LV remodeling than those 
without focal fibrosis, diffuse fibrosis independently predicted 
LV reverse remodeling in DCM patients despite the presence of 
focal fibrosis [40]. Our group also observed that post-contrast 
T1 is closely related to LV remodeling, diastolic function and 
neurohormonal activation, measured by NT-proBNP level [41]. 
Barison et al. [42] showed myocardial ECV was an independent 
prognostic predictor beyond all other conventional clinical, 
electrocardiographic and echocardiographic parameters. Also, 
Chen et al. [27] demonstrated that quantitative myocardial tis-
sue assessment using T1 mapping was an independent predic-
tor of ventricular arrhythmia in both ischemic and non-isch-
emic cardiomyopathies. Regarding cardiac resynchronization 
therapy response, focal scar burden detected by LGE-CMR was 
associated with a poor response to cardiac resynchronization 
therapy. A previous study showed that diffuse interstitial fibrosis 
assessment by T1 mapping, however, was not independently 
predictive of cardiac resynchronization therapy response [43]. 
Recently, an important prospective multicenter longitudinal study 
in 637 consecutive patients with DCM {mean age 50 years [in-
terquartile range (IQR) 37–76 years]; 395 males [62%]} under-
went CMR with T1 mapping and LGE at 1.5 T and 3.0 T field 
strengths. During a median follow-up period of 22 months (IQR 
19–25 months), a total of 28 deaths (22 cardiac) and 68 compos-
ite HF events were observed. T1 mapping indices (native T1 and 
ECV), as well as the presence and extent of LGE, were predic-
tive of all-cause mortality and HF endpoint (p<0.001 for all). 
Multivariate analyses showed native T1 was the sole indepen-
dent predictor of all-cause and HF composite endpoints (HR, 
1.1; 95% CI: 1.06–1.15; HR, 1.1; 95% CI: 1.05–1.1; p<0.001 for 
both), followed by the models including the extent of LGE and 
right ventricular EF, respectively (Fig. 4) [44].
Cardiac amyloidosis and sarcoidosis
Although native T1 and ECV data are helpful for early detec-
tion of cardiac involvement in systemic amyloidosis or suspected 
cardiac amyloidosis [45-47], the prognostic value of T1 map-
ping is rarely reported. T1 mapping can also provide informa-
tion about disease severity and serve as a monitoring tool for che-
motherapy in amyloid light-chain amyloidosis [48]. Banypersad 
et al. [49] showed ECV was independently predictive of mortal-
ity (HR, 4.41; 95% CI: 1.35–14.4) after adjusting for E/e’, EF, dia-
stolic dysfunction grade and NT-proBNP, but not with native T1 
data in light chain amyloidosis. Greulich et al. [50] reported that 
sarcoid patients had a higher median native T1 (994 vs. 960 ms; 
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p<0.001), lower post-T1 (491 vs. 526 ms; p=0.001), expanded 
extracellular volume (28 vs. 25%; p=0.001), and higher T2 values 
(52 vs. 49 ms; p<0.001) compared with controls. Thus, patients 
with sarcoidosis demonstrated higher T1 values, extracellular 
volume, and T2 values compared to healthy controls, with the 
most significant differences seen in native T1 and T2 data. 
Tachycardia-induced cardiomyopathy
A recent study showed that compared with controls, atrial 
tachycardia with low EF patients had reduced global LV cor-
rected post-T1 times (442±53 vs. 529±61 ms; p<0.05), consis-
tent with diffuse fibrosis. Tachycardia-mediated cardiomyopa-
thy patients exhibited differences in LV structure and function 
including diffuse fibrosis long after arrhythmia cure, indicating 
that recovery was incomplete [51].
Acute and chronic myocarditis
Limited data are available regarding the degree of normaliza-
tion of CMR parameters during the course of the disease and 
the time window during which quantitative CMR should be 
most reasonably implemented for diagnostic work-up. Regard-
ing this question, Luetkens et al. [52] reported that there was a 
significant and consistent decrease in all inflammatory CMR 
parameters over the course of the disease (p<0.01 for all param-
eters). Myocardial T1 and T2 relaxation times-indicative of myo-
cardial edema-were the only single parameters showing signifi-
cant differences between myocarditis patients and control subjects 
at the 5.5±1.3-week follow-up (native T1: 986.5±44.4 vs. 965.1± 
Fig. 4. (A) Native T1 [normal vs. abnormal myocardium, based on >2 standard deviations (SD) above the mean of the normal reference 
range]. (B) Native T1 ranked by 2n-times SD (ranks of SD: <2, ≥2 to 4, ≥4 to 6, ≥6), (C) LGE present vs. absent and (D) LVEF <35% 
(Adapted from Puntmann et al. JACC Cardiovasc Imaging 2016;9:40-50. [44]). HR: hazard ratio, LGE: late gadolinium enhancement, LVEF: 
left ventricular ejection fraction, HF: heart failure.
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28.1 ms, p=0.022; T2: 55.5±3.2 vs. 52.6±2.6 ms, p=0.001). They 
concluded that myocardial native T1 and T2 relaxation times 
were the only active inflammation/edema parameters that could 
discriminate between myocarditis patients and control subjects 
even during the convalescent stage of the disease. von Knobels-
dorff-Brenkenhoff et al. [53] reported that although both T2 and 
T1 mapping reliably detected acute myocarditis, only T2 mapping 
discriminated between acute and healed stages, underlining the 
incremental value of T2 mapping.
Prognostic value in valvular heart diseases
Aortic stenosis
As patient numbers increase, the role of prognostication be-
comes important, especially in fragile patients. Current issues 
include peri-surgical aortic valve replacement or peri-trans-
catheter aortic valve replacement (TAVR) risk stratification. 
From this point of view, LGE presence and amount provides 
useful prognostic information [54,55], but the additive prognos-
tic value of T1 mapping remains unclear. Some previous reports 
revealed that ECV or native T1 values could be helpful for the 
prediction of arrhythmic events or complete atrio-ventricular 
(AV)-block after the TAVR procedure [56]. For example, pa-
tients with post-TAVR conduction abnormality (left bundle 
branch block, AV-block or pacemaker implantation) had statisti-
cally significantly lower ECV values compared to those without 
an event. Patients with an event had a mean ECV of 28.1±3.16%; 
patients without an event had a mean ECV of 29.8±4.53% (HR, 
0.56; 95% CI: 0.32-0.96, p=0.036). In this study, elevated myocar-
dial ECV was a trending predictor of HF; CMR may be helpful 
in identifying patients at high risk for post-TAVR cardiac de-
compensation benefitting from intensified post-interventional 
surveillance [56]. So CMR-T1 mapping can guide selection of 
TAVR-valve type, which results in less conduction system com-
promise in cases with a high risk of conduction disturbance. In 
addition, elderly persons and those with chronic kidney disease 
are very common in cases with severe aortic stenosis, so native 
T1 without contrast could provide helpful information without 
the use of gadolinium contrast media [57,58]. Chin et al. [59] 
used total extracellular volume indexed by body surface area 
(iECV) was together with LGE to categorize patients with nor-
mal myocardium (iECV<22.5 mL/m2; 51% of patients), extra-
cellular expansion (iECV≥22.5 mL/m2; 22%), and replacement 
fibrosis (presence of mid-wall LGE, 27%). In that study, catego-
rization by ECV was of prognostic value with stepwise increases 
in unadjusted all-cause mortality (8 deaths/1000 patient-years 
vs. 36 deaths/1000 patient-years vs. 71 deaths/1,000 patient-
years, respectively; p=0.009).
Mitral regurgitation and aortic regurgitation
A few studies have shown that the presence of preoperative 
myocardial fibrosis assessed with LGE-CMR was an indepen-
dent predictor of increased adverse clinical outcomes in pa-
tients with chronic degenerative mitral regurgitation [60,61]. 
Chaikriangkrai et al. [61] reported that preoperative LGE may 
be of clinical utility for the prediction of outcomes during peri-
mitral valve repair. Myocardial ECV was increased (32±7% vs. 
25±2%, p<0.01) in severe mitral regurgitation patients com-
pared to healthy controls. ECV was associated with increased 
LV end-systolic volume index (r=0.62, p<0.01), left atrial volume 
index (r=0.41, p<0.05), lower LV EF (r=-0.60, p< 0.01), longi-
tudinal function (mitral annular plane systolic excursion, r=-
0.46, p<0.01) and peak VO2 max (r=-0.51, p<0.05). A multi-
variate regression model showed LV end-systolic volume index 
and left atrial volume index were independent predictors of 
ECV (r2=0.42, p<0.01) [58,62]. A recent study by Bui et al. [63] 
reported that patients with mitral valve prolapse with complex 
ventricular arrhythmia (ComVA) had significantly shorter post-
T1 times when compared with patients with mitral valve prolapse 
without ComVA [324 (IQR 296–348) vs. 354 (IQR 327–376) 
ms; p=0.03] and only 5/14 (36%) had evidence of papillary mus-
cle LGE. Mitral valve prolapse may be associated with diffuse 
LV myocardial fibrosis as suggested by reduced post-T1 times. 
They concluded that diffuse interstitial derangement was linked 
to subclinical systolic dysfunction, and may have contributed 
to ComVA in mitral valve prolapse-related mitral regurgitation, 
even in the absence of focal fibrosis. Prediction of LV function 
after mitral valve or aortic valve surgery in cases with severely 
depressed LV function is challenging. Due to prediction uncer-
tainty for LV function recovery, several parameters are poten-
tial predictors [64]. The basic concept of reversibility prediction 
is based on degree of myocardial fibrosis, especially diffuse inter-
stitial fibrosis. At this point, ECV or native T1 values are helpful 
indexes. However, few studies have examined this issue. LGE 
positive signal in CMR is a potential predictor of persistent car-
diac failure after aortic valve replacement for patients with severe 
chronic aortic regurgitation and an extremely dilated LV cham-
ber. This has an intimate relationship with malignant arrhythmia 
and sudden death, which makes this a valuable technique in pre-
operative evaluation and risk stratification [60,65]. However, 
no T1 mapping-based prognostication studies in severe aortic re-
gurgitation patients have yet been conducted.
Perspectives and challenges
Because there is already a great deal of evidence for LGE 
prognostication, T1 mapping-based parameters should pro-
vide additive information beyond that provided by LGE. How-
ever, quantification of LGE amount for various cardiac diseases, 
especially in cardiomyopathies, shows measurement variability 
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[66,67]. In contrast, measurement of average ECV or native T1 
in whole LV myocardium is more convenient for researchers. 
Therefore, a head-to-head comparison asking which parameter 
(amount of LGE and average T1) is better for prognostication is 
needed, because there is an increase in the number of HF pa-
tients, an aging population and an increasing prevalence of 
concomitant kidney disease. Although a far improvement for 
avoiding systemic nephrogenic fibrosis, gadolinium usage is 
still limited in patients with glomerular filtration rates less than 
45 mL/min/m2. In those cases, native T1-based imaging would 
provide safe and reliable information about myocardial tissue 
characteristics [68]. After establishment of a standardization 
protocol for image acquisition and motion correction algorithm, 
it could be used in various centers and multi-nations around the 
world. Most importantly, the protocol could be used as a sensi-
tive and reliable tool to demonstrate the effects of new treat-
ments.
CONCLUSION
In regard to risk stratification and prognostication for car-
diovascular events including sudden death, current evidence is 
mainly focused on non-ischemic cardiomyopathy such as 
HCM and DCM. However, a growing number of studies have 
demonstrated the role of T1 in risk stratification in various dis-
ease entities, including ischemic and valvular heart disease.
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